Description:
A two arm pilot study investigating the rate of pathologic complete response in patients with
vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant
chemotherapy + vitamin D supplementation, including an observational arm to describe response
in patients who are not deficient. Investigators hypothesize that vitamin D supplementation
during neoadjuvant chemotherapy in operable triple negative breast cancer patients with
vitamin D deficiency, will increase the rate of pathologic complete response chain reaction
to that of vitamin D sufficient patients based on historical controls.
Title
- Brief Title: Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
- Official Title: Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
IRB00074154
- SECONDARY ID:
WFBCCC 98121
- SECONDARY ID:
P30CA012197
- NCT ID:
NCT04677816
Conditions
- Triple Negative Breast Cancer
- Vitamin D Deficiency
- Invasive Breast Cancer
Interventions
| Drug | Synonyms | Arms |
|---|
| Standard of Care Neoadjuvant Chemotherapy | | Observational Arm - Vitamin D at Normal Levels |
Purpose
A two arm pilot study investigating the rate of pathologic complete response in patients with
vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant
chemotherapy + vitamin D supplementation, including an observational arm to describe response
in patients who are not deficient. Investigators hypothesize that vitamin D supplementation
during neoadjuvant chemotherapy in operable triple negative breast cancer patients with
vitamin D deficiency, will increase the rate of pathologic complete response chain reaction
to that of vitamin D sufficient patients based on historical controls.
Detailed Description
Primary Objective: To determine if pathologic complete response in vitamin D deficient
patients receiving vitamin D supplementation during neoadjuvant chemotherapy for operable
triple negative breast cancer is greater than or equal to 60% or less than or equal to
pathologic complete response in historical controls (30%) using a one-stage phase II design.
Secondary Objective(s):
- To estimate the proportion of patients with residual cancer burden (RCB) classes I, II,
and III in vitamin D deficient patients receiving vitamin D supplementation during
neoadjuvant chemotherapy for operable triple negative breast cancer.
- To estimate pathologic complete response reaction in the observational arm of vitamin D
sufficient patients receiving neoadjuvant chemotherapy for operable triple negative
breast cancer.
- To determine the feasibility of delivery of vitamin D supplementation with standard of
care chemotherapy.
- To determine the safety and tolerability of the combination of vitamin D supplementation
with standard of care chemotherapy.
- To estimate the change in vitamin D receptor (VDR) expression from pre- and
post-neoadjuvant treatment breast tumor tissue samples of vitamin D deficient patients.
- To estimate the change in VDR expression from pre- to post-neoadjuvant treatment breast
tumor tissue samples in a sample of 5 vitamin D sufficient patients.
- To estimate the changes in the fecal microbiome and mammary gland microbiome of vitamin
D deficient patients from pre- to post-neoadjuvant treatment, and to explore the
concordance in the changes between the mammary and fecal microbiome.
- To estimate the changes in the fecal microbiome and mammary gland microbiome in a sample
of 5 vitamin D sufficient patients from pre- to post-neoadjuvant treatment.
Patients will be followed for a minimum of 30 days after the last study intervention is
administered for adverse events monitoring.
Patients will be followed for 30 days after removal from study or until death, whichever
occurs first. Patients removed from study for unacceptable adverse events will be followed
until resolution or stabilization of the adverse event.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Vitamin D Supplementation Group - Deficient Levels | Experimental | Along with standard of care neoadjuvant chemotherapy treatments and procedures, participants will receive oral 50,000 international units of Vitamin D3 supplementation at the initiation of chemotherapy once a week. | - Standard of Care Neoadjuvant Chemotherapy
|
| Observational Arm - Vitamin D at Normal Levels | Active Comparator | Standard of care neoadjuvant chemotherapy | - Standard of Care Neoadjuvant Chemotherapy
|
Eligibility Criteria
Inclusion Criteria:
- Women or men with histologically confirmed invasive mammary carcinoma.
- Known triple negative ER/PR/HER2 receptor status as defined by:
- ER and PR < 10% and
- HER2 negative based on one of the following:
- IHC 0 or 1+
- IHC 2+ and FISH negative
- IHC 2+ and FISH equivocal and no indication for HER2 targeted therapy based on
the treating investigators discretion (i.e., HER2: CEP17 ratio < 2.0 or HER2
total copy number <6)
- Patients who are scheduled to undergo definitive surgical treatment with lumpectomy or
mastectomy with axillary lymph node staging after neoadjuvant chemotherapy.
- ECOG performance status of 0, 1 or 2.
- Age ≥ 18.
- The effects of high dose vitamin D on the developing human fetus are unknown. For this
reason, women of child-bearing potential must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately.
- Ability to understand and the willingness to sign an IRB-approved informed consent
document (either directly or via a legally authorized representative).
Exclusion Criteria:
- Patients with nephrolithiasis within the past year.
- Patients with known sarcoidosis.
- Patients with corrected calcium >10.5 mg/dL within 30 days prior to initiation of
chemotherapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to vitamin D.
- Pregnant women are excluded from this study because vitamin D supplementation greater
than the recommended daily allowance (RDA) is a pregnancy class C agent with no
adequate or well controlled studies in humans.
- Because there is an unknown but potential risk for adverse events in nursing infants
secondary to treatment of the mother with high dose vitamin D (greater than RDA),
women who are breastfeeding are excluded from this study.
- Prior treatment for this malignancy including surgery, radiation therapy,
chemotherapy, hormonal therapy or investigational agent prior to study entry.
- Patients currently taking Vitamin D at a dose of 50,000 International Units (IU) once
weekly.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Number of Pathologic Complete Response (pCR) in Vitamin D Supplementation Group |
| Time Frame: | Up to 4 weeks |
| Safety Issue: | |
| Description: | Investigators will determine whether the proportion responding (pCR) is less than or equal to 30% or greater than or equal to 60% using a one-stage phase II design. All participants in the intervention group who are evaluable will be included in the analysis. Pathologic complete response, which is also characterized as residual cancer burden 0, is defined as a final surgical pathologic diagnosis of ypT0 ypN0 or ypTis ypN0. |
Secondary Outcome Measures
| Measure: | Number of Participants with Residual Cancer Burden (RCB) Index - Vitamin D Supplementation Group |
| Time Frame: | Up to 20 weeks |
| Safety Issue: | |
| Description: | Five variables are included in the calculation formula. These include: 1) Primary tumor bed area, defined as the largest two dimensions (mms) of the residual tumor bed in the breast (largest tumor bed if multicentric disease), 2) Overall cancer cellularity (as percentage of area), 3) Percentage of cancer that is in situ disease, 4) Number of positive lymph nodes and 5) Diameter of largest metastasis. The calculated residual cancer burden index will be categorized as one of four residual cancer burden classes RCB-0 (pathologic complete response), minimal residual disease (RCB-I), moderate residual disease (RCB-II), or extensive residual disease (RCB-III). |
| Measure: | Number of Participants with Residual Cancer Burden (RCB) Index - Observational Arm |
| Time Frame: | Up to 20 weeks |
| Safety Issue: | |
| Description: | Five variables are included in the calculation formula. These include: 1) Primary tumor bed area, defined as the largest two dimensions (mms) of the residual tumor bed in the breast (largest tumor bed if multicentric disease), 2) Overall cancer cellularity (as percentage of area), 3) Percentage of cancer that is in situ disease, 4) Number of positive lymph nodes and 5) Diameter of largest metastasis. The calculated residual cancer burden index will be categorized as one of four residual cancer burden classes RCB-0 (pathologic complete response), minimal residual disease (RCB-I), moderate residual disease (RCB-II), or extensive residual disease (RCB-III). |
| Measure: | Accrual Rate |
| Time Frame: | Up to 20 weeks |
| Safety Issue: | |
| Description: | Will be calculated as the number of women who agreed to participate divided by the number of months of recruitment. Estimates and 95% confidence intervals will be calculated for all study participants and for the subset of evaluable participants. |
| Measure: | Participation Rate |
| Time Frame: | Up to 20 weeks |
| Safety Issue: | |
| Description: | Will be calculated as the percent of eligible participants who agreed to participate. Estimates and 95% confidence intervals will be calculated for all study participants and for the subset of evaluable participants. |
| Measure: | Retention Rate |
| Time Frame: | Up to 20 weeks |
| Safety Issue: | |
| Description: | Will be calculated as the number of participants on whom investigators can obtain the final surgery pathology report by the number who consented to participate. Estimates and 95% confidence intervals will be calculated for all study participants and for the subset of evaluable participants. |
| Measure: | Adherence Rate |
| Time Frame: | Up to 20 weeks |
| Safety Issue: | |
| Description: | will be defined by the proportion of Vitamin D supplements consumed and the proportion of women who took at least 80% of pills. Estimates and 95% confidence intervals will be calculated for all study participants and for the subset of evaluable participants. |
| Measure: | Number of Adverse Events |
| Time Frame: | Up to 30 days after last day of study intervention |
| Safety Issue: | |
| Description: | To determine safety of intervention all adverse events will be documented and analyzed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for adverse event reporting using frequencies of events, grade and attribution. |
| Measure: | Change in Vitamin D Receptor (VDR) Expression |
| Time Frame: | At baseline and up to 30 days after surgery |
| Safety Issue: | |
| Description: | Investigators will use a paired t-test to examine the change in Vitamin D receptor expression from pre-post neoadjuvant treatment. |
| Measure: | Change in Fecal Microbiomes |
| Time Frame: | At baseline and up to 30 days after surgery |
| Safety Issue: | |
| Description: | Investigators will examine the proportion of different bacteria taxa at each time point, and will use a marginalized two-part beta regression model to account for the compositional nature of the data. A list of all the microbiologic species will be recorded, along with their relative abundance recorded as a percentage relative abundance of the total microbiome. |
| Measure: | Change in Mammary Gland Microbiomes |
| Time Frame: | At baseline and up to 30 days after surgery |
| Safety Issue: | |
| Description: | Investigators will examine the proportion of different bacteria taxa at each time point, and will use a marginalized two-part beta regression model to account for the compositional nature of the data. A list of all the microbiologic species will be recorded, along with their relative abundance recorded as a percentage relative abundance of the total microbiome. |
Details
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | Wake Forest University Health Sciences |
Last Updated
June 30, 2021
